Welcome to our dedicated page for Better Choice Co news (Ticker: BTTR), a resource for investors and traders seeking the latest updates and insights on Better Choice Co stock.
Better Choice Co Inc (NYSE: BTTR) is a leader in premium pet health solutions, specializing in natural nutrition and wellness innovations. This page aggregates all official corporate announcements, financial disclosures, and market developments.
Investors and industry stakeholders will find curated updates including earnings reports, product launches, strategic partnerships, and regulatory filings. Content spans key operational areas: natural pet food formulations, CBD supplements research, retail distribution expansions, and sustainability initiatives.
All materials are sourced directly from SEC filings, verified press releases, and executive communications. Bookmark this page for real-time updates on BTTR's progress in advancing pet wellness through science-backed solutions and ethical business practices.
Better Choice Company (NYSE: BTTR) has announced that SRx Health Solutions has signed a definitive agreement to convert CAD$4 million in debt to equity. This strategic move is expected to improve SRx Health's working capital position and future cash flow. The debt conversion is contingent upon the completion of the pending merger between Better Choice and SRx Health Solutions, scheduled for late-April 2025. Upon merger completion, the combined entities aim to establish themselves as a leading global health and wellness company, focusing on integrated healthcare solutions for pets, people, and families.
Better Choice Company (NYSE: BTTR) reported strong Q4 2024 financial results with revenue growth of 26% year-over-year to $7.2 million, driven by a 32% increase across Chewy and Amazon platforms. The company demonstrated significant improvements with gross margin expanding to 36%, representing a 2,705 basis point increase year-over-year.
Q4 2024 highlights include a 90% improvement in net loss to $(1.6) million, and loss per share improving 97% to $(0.50). The adjusted EBITDA loss improved 80% to $(0.7) million. For full-year 2024, the company achieved a $6.2 million gain on debt extinguishment, with net loss improving 99% to $(0.2) million and loss per share improving 100% to $(0.10).
The company maintained a healthy working capital position of $7.9 million, with $3.1 million in cash and cash equivalents and $2.4 million available in credit facility borrowing capacity as of December 31, 2024.
Better Choice Company (NYSE: BTTR), a pet health and wellness company, has announced its participation in the upcoming 2025 Bloom Burton & Co. Healthcare Investor Conference. The event will take place at the Metro Toronto Convention Centre in Toronto, Ontario on May 5-6, 2025.
The company's management team from SRx Health will deliver their presentation on Tuesday, May 6, 2025, at 3:30 p.m. ET. Investors can access the presentation through the company's investor relations website. Additionally, management will be available for one-on-one meetings throughout the conference, which can be arranged through Bloom Burton & Co. representatives or by contacting KCSA directly.
Better Choice Company (NYSE American: BTTR) shareholders have overwhelmingly approved key proposals at a special meeting held on March 21, 2025. The approved measures include: the issuance of up to 30 million shares of common stock for the acquisition of SRx Health Solutions, a change in company name to 'SRX Health Solutions, Inc.', and a ticker symbol change from 'BTTR' to 'SRXH'.
The meeting saw strong shareholder participation with 1,419,942 shares voted, representing 71.71% of total outstanding shares. The acquisition is positioned as a strategic move to transform Better Choice into a leading global health and wellness company, with closing expected in the coming weeks.
Better Choice Company (NYSE: BTTR) has announced a significant shareholder royalty distribution plan approved by its Board of Directors. Under this new initiative, up to 55% of annual royalties generated by the company's flagship Halo brand will be distributed to stockholders of record as of December 31 each year.
The aggregate distribution amount will be determined annually by the Board of Directors through appropriate Board action. According to Chairman Michael Young, this unique royalty distribution plan demonstrates Better Choice's commitment to delivering long-term shareholder value from their premium pet nutrition brand Halo.
Better Choice Company (NYSE American: BTTR) has signed a binding Letter of Intent to acquire Choice Specialty Pharmacy Group, a specialized pharmacy services provider in the U.S. The acquisition price will be based on 6X of Choice Specialty's FY2024 Adjusted EBITDA of approximately $4.68 million, paid through a combination of stock and cash.
Founded in 2015, Choice Specialty Pharmacy Group operates across multiple states, providing specialty pharmacy services, infusion clinic services, and maintains a sterile compounding facility. This strategic move will expand Better Choice's presence in the U.S. market and complement their existing SRx platform in Canada.
The acquisition aligns with Better Choice's strategy to establish itself as a prominent healthcare services company in North America, leveraging operational synergies and best practices from both organizations.
Better Choice Company (NYSE: BTTR), a pet health and wellness company, has scheduled its Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 27, 2025, at 4:30 p.m. ET. The company will present financial performance and provide a business update.
The conference call will be accessible via phone at 1-888-348-8935 or 1-412-317-0454, and through a webcast. For those unable to attend live, a replay will be available for 90 days on the company's website under the 'Events & Presentations' section.
Additionally, Better Choice has filed a supplemental proxy statement as part of their commitment to transparency and shareholder engagement.
Better Choice Company (NYSE: BTTR) has appointed Dr. Paldeep S. Atwal as its United States Special Healthcare Advisor. Dr. Atwal, a board-certified clinical and medical biochemical geneticist, brings extensive expertise in rare diseases and genomic medicine to the pet health and wellness company.
Dr. Atwal is the founder of Atwal Clinic for Genomic & Personalized Medicine in Palm Beach, FL, and previously served as Medical Director at both Everly Health Solutions and Mayo Clinic Florida's Individualized Medicine Clinic. The appointment comes as Better Choice approaches the completion of its SRx Health acquisition.
Chairman Michael Young emphasized that Dr. Atwal's expertise will be important for accelerating company growth, particularly in developing new offerings and strategic healthcare partnerships. Dr. Atwal's background includes notable achievements such as the ACMG Foundation/Genzyme Fellowship and training at prestigious institutions including Stanford University and Baylor College of Medicine.
Better Choice Company (NYSE: BTTR) announced that SRx Health Solutions has received the final Order from the Ontario Superior Court of Justice to proceed with its acquisition by Better Choice. The company will hold a Special Meeting on March 21, 2025, at 9:00 a.m. ET, exclusively via webcast.
Stockholders of record as of January 21, 2025, are eligible to vote at the meeting, even if they have sold their shares since then. Previously submitted proxies will remain valid for all proposals unless properly revoked. Better Choice plans to file and distribute a supplementary Proxy Statement with the SEC to ensure stockholders have adequate time to review updated materials and make informed voting decisions.
Better Choice Company (NYSE American: BTTR) announced that shareholders of SRx Health Solutions have overwhelmingly approved the proposed acquisition, with approximately 93% voting in favor. Better Choice will hold its Special Meeting on March 21, 2025, at 9:00 a.m. ET via live webcast for its stockholders to vote on the acquisition.
The record date for stockholder voting eligibility remains January 21, 2025, and stockholders as of this date can vote even if they have since sold their shares. Previously submitted proxies will be valid for all proposals unless properly revoked. The company plans to file and distribute a supplementary Proxy Statement with the SEC to ensure stockholders have adequate time to review updated materials and make informed voting decisions.
